Contact hypersensitivity (CH) has served as a useful model for investigating the allergen-specific immune responses of T cells and skin-associated antigen-presenting cells. We examined the distinct role between CD80 and CD86 on hapten-lnduced CH in both an induction and an effector phase. Intraperltoneal injection of mAb against CD86, but not CD80, 2 h before sensitizatlon with epicutaneous application of dinttrofluorobenzene led to an almost complete inhibition of ear swelling, and histologically a marked reduction of edema, Inflammatory polymorphonuclear cells and lymphocyte Infiltration In the dermis. In contrast, the administration with either anti-CD80 or CD86 mAb 2 h before challenge partially inhibited CH reactions and a combination of both mAb did not improve the inhibitory effect Although Langerhans cells (LC) expressing MHC class II were observed in both the epidermis and dermis 24 h after primary sensitizatlon, CD86 + LC were observed only In the subepidermal regions and CD80-bearing cells were not detected. Dendritic cells (DC) expressing both CD80 and CD86 were preferentially observed in the T cell areas of draining lymph nodes 24 h after challenge. The administration of anti-CD8€ mAb In the induction phase prominently reduced the up-regulatlon of CD80 and CD86 on DC In the lymph nodes. The predominant role of CD86 was further supported by a marked reduction In proliferation of lymph node T cells against the sensitized hapten after the antl-CD86 treatment. These results suggest that CD86 plays a critical role in the initiation of primary immune responses In the skin, while CD80 and CD86 are not essential in the effector phase of CH reactions.
Introduction
An optimal antigen-specific T cell activation requires two distinct signals (1, 2) . One originates from the ligation of the TCR and the second signal is provided by the direct interaction between co-stimulatory molecules on T cells and their ligands on antigen-presenting cells (APC). It is generally accepted that the signal through the binding of CD28 on T cells with its ligands, CD80 (B7/BB1, B7-1) and CD86 (B70, B7-2), on APC is a crucial co-stimulatory pathway (3) (4) (5) . CD80 and CD86 are expressed on professional APC such as dendritic cells (DC), monocytes and macrophages. Only subpopulations of freshly isolated, non-cultured murine splenic DC and human peripheral blood DC and monocytes constitutively express CD86, but not CD80 (6) (7) (8) . However, the expression of both CD80 and CD86 can be augmented by culture with various stimuli (7, (9) (10) (11) . In contrast to the constitutive expression of CD86 on DC and monocytes, substantial expression of either CD80 or CD86 was not observed on freshly isolated epidermal Langerhans cells (LC) or in situ in tissues, but culture with media or several cytokines is capable of inducing the expression of both CD80 and CD86 on LC (6, (12) (13) (14) .
The skin allergic contact hypersensitivity (CH) response is a classical animal model for delayed-type hypersensitivity (DTH), which results from cellular immune responses mediated by T h 1 cells. Epidermal LC are the principal APC in CH reactions. Contact with allergens results in the increased expression of MHC class II molecules on LC (15) , which then migrate to regional lymph nodes (16) where they induce primary T cell responses. However, the actual molecular events involved in these reactions have not yet been completely understood. It was reported that IL-1P is a critical cytokine produced by LC after exposure to contact allergen (17) , and that IL-10 (18, 19) or UV-B radiation (20) inhibits antigen-presenting function of LC and reduces the CH reaction. In addition, recent reports suggest that the inhibition of the antigen-presenting function of LC or peripheral DC by IL-10 or UV-B radiation results from a failure in up-regulation of CD86 (14, (21) (22) (23) . Thus, the regulation of CD80 and CD86 on LC seems to play an important role in antigen-specific T and LC interactions in the skin. To clarify the direct involvement of CD80 and CD86 molecules in CH reactions, we examined the effect of in vivo administration of anti-CD80 and/or anti-CD86 mAb on hapten-induced CH reactions and the in situ expression of these molecules in the skin and draining lymph nodes.
Methods

Mice
Female BALB/c mice were obtained from Japan SLC (Hamamatsu, Shizuoka, Japan) and used at 7-8 weeks of age.
Generation of anti-CD80 and -CD86 mAb
Rat anti-mouse CD80 mAb (RM80, lgG2a) and CD86 mAb [PO1 (IgM), PO2 (lgG2b), PO3 (lgG2b), PO4 (lgG1) and PO5 (lgG2a)] were obtained from a fusion of P3U1 myeloma cells with SD rat splenocytes immunized with BCL1 cells expressing large amounts of both CD80 and CD86 or J774 cells expressing high level of CD86 antigen alone. The specificity of mAb was confirmed by specific reactivity with a murine mastocytoma P815 cell lines transfected with either murine CD80 or CD86 cDNA, as described previously (24) . RM80 reacted with CD80-P815 but not with CD86-P815, while mAb PO1-5 reacted with CD86-P815 but not with CD80-P815 (not shown). In agreement with previous results (25, 26) , mAb PO2-5 precipitated a single molecule of -65 kDa from the lysate of BCL1 cells under reducing conditions (data not shown). These mAb were purified from ascites by standard procedures using caprylic acid extraction and the purity of mAb was verified by SDS-PAGE analysis.
mAb GL1 (anti-CD86, rat lgG2a) and 1G10 (anti-CD80, rat lgG2a) were obtained from PharMingen (San Diego, CA). For immunohistochemical analysis, anti-l-A(M5/114.15.2, rat lgG2b), anti-CD4 (GK1.5, rat lgG2b), anti-CD80 (RM80) and anti-CD86 (PO3) were used. Hybridomas producing mAb against I-A, CD4, CD3 (2C11, hamster IgG) and CD24 (J11d, rat IgM) were obtained from the American Type Culture Collection (Rockville, MD).
Assay for contact hypersensitivity
CH was induced by sensitization with 0.5% of dinitrofluorobenzene (DNFB; Sigma, St Louis, MO) or 5% trinitrochlorobenzene (TNCB; Tokyo Kasei, Tokyo, Japan) dissolved in acetone:olive oil (4:1) by painting to the shaved abdominal skin of BALB/c mice on two consecutive days (days 0 and 1). Three days after the final sensitization (day 4), mice were challenged on both surfaces of the ears with 10 nl of 0.2% DNFB or 1% TNCB. The ear thickness was measured using a dial thickness gauge (Peacock, Ozaki, Tokyo, Japan). Measurement of each lobe was repeated and a total of four measurements per mouse was performed. The ear thickness was measured before and 24 h after challenge, since preliminary experiments on the time-kinetics of ear swelling demonstrated maximal responses at 24 h. The individual value of ear swelling was taken as the mean value of four measurements per mouse post-challenge minus the mean value before challenge. The ear thicknesses from mice that were painted with the vehicle control (acetone/olive oil) alone and then were challenged are presented as negative controls.
Antibody treatment
Each group of four to six mice received i.p. injection with 250 ^g/mouse of the indicated mAb in a total volume of 0.5 ml 2 h prior to every sensitization or challenge. The mice in control groups received either PBS or 250 ng/mouse of irrelevant rat Ig (Sigma). The percent suppression was calculated according to the formula: % suppression = (1 -net ear swelling in treated mice/ net ear swelling in PBS-treated mice)xi00.
CD86 co-stimulation assay
Splenic T cells from BALB/c mice were purified by passage through nylon-wool columns and treatment with anti-l-A and anti-CD24 mAb and rabbit complement. Purified T cells were co-cultured with irradiated (80 Gy) CD86-P815 in the presence of anti-CD3 (2C11, 2 ng/ml) mAb. Blocking mAb were added at the start of the assay at the indicated concentrations. Cultures were pulsed with [ 
Hapten-specific T cell proliferation assay
Lymph nodes from normal mice and draining regional lymph nodes from the mice treated with either PBS, RM80 or PO3 at the time of TNCB sensitization and unsensitized negative control mice were surgically removed 72 h after the final sensitization and the T cells were purified as described above. Purified T cells (2xiO s /well) were co-cultured with the indicated number of trinitrobenzensulfonate (TNBS)-pulsed or unpulsed normal irradiated (30 Gy) splenocytes in 96-well flat-bottom plates as previously described (19) . Cultures were pulsed with 1.0 (iCi/well [ 3 H]thymidine for the last 16 h of a 72 h incubation.
Histological examination
Tissue specimens of the ears and regional lymph nodes from the treated or untreated mice were surgically removed immediately after determination of ear swelling, embedded in OCT compound (Tissue-tek®, Miles, IN), frozen in liquid nitrogen and stored at -70°C until used. Cryostat sections of 3-4 urn thickness were fixed in absolute acetone. For immunohistochemical staining, the sections were incubated with either rat anti-mouse MHC class II (M5/114), CD4 (GK1.5), CD80 (RM80) or CD86 (PO3) mAb after blocking with 10% normal rabbit serum and then incubated with secondary biotinylated rabbit anti-rat Ig (\fector, Burlingame, CA). Localization of antigen-antibody complexes was performed by treatment with peroxidase-conjugated ABC complex (Vectastain ABC; Vector) and the substrate, diaminobenzidine. Between each incubation the sections were rinsed in PBS. Finally, the sections were rinsed in distilled water and counterstained with methyl green. Specificity of positive staining was confirmed on every section by the absence of staining with the-secondstep reagent alone. Alternate sections were stained with H&E.
Statistical analysis
Student's f-test was performed to determine the statistical significance of ear swelling responses.
Results
Inhibitory effects of anti-CD86 mAb in vitro
In order to evaluate the functional inhibitory effects of anti-CD86 mAb, we performed a CD86-co-stimulation assay. Purified splenic T cells were co-cultured with CD86-P815 transfectants in the presence of a suboptimal dose of anti-CD3 mAb and the serial dilutions of each anti-CD86 mAb were added to the culture. As shown in Fig. 1 , the highest amount (50 ng/ml) of all anti-CD86 mAb, including a commercially available GL1 mAb, almost completely inhibited the CD86-dependent proliferation of T cells, and this inhibitory effect occurred in a dose-dependent manner. Lower amounts (0.05-0.005 |ig/ml) of mAb caused partial inhibitions, especially in the case of PO2, PO4 and PO5, suggesting that these three mAb have relatively less inhibitory efficacy. In previous experiments using a similar assay system, we demonstrated that the blocking ability of PO3 in CD86-dependent T cell proliferation was comparable to that of RM80 in CD80-dependent proliferation (24) .
Treatment with anti-CD86 mAb in the induction phase efficiently inhibits CH reaction
CH is a form of DTH in which the target organ is the skin and the inflammatory response is elicited by the epicutaneous application of a reactive hapten. The response consists of an induction phase at the sensitization and an effector phase at the hapten challenge. We first investigated the effect of anti-CD80 (RM80) and/or anti-CD86 (PO3) mAb on the induction phase of CH reactions. Two hundred and fifty microgram of either RM80, PO3 or both mAb in 0.5 ml PBS or the same volume of control reagents was administered i.p. 2 h prior to every sensitization with DNFB and the ear swelling at 24 h post-DNFB challenge was examined. We present the data from PBS-treated mice as a control group in the following all experiments, since we observed no differences between mice treated with PBS and irrelevant rat Ig in our preliminary experiments. Administration of anti-CD86 mAb resulted in an almost complete inhibition of the ear swelling compared with the PBS-treated control group, while the treatment with anti-CD80 mAb did not affect ear swelling ( Fig. 2A) . The in vivo inhibitory efficacy of individual anti-CD86 mAb seemed to correlate with their blocking ability in CD86-co-stimulated T cell proliferation in vitro, since PO2 and PO4 exhibited less inhibitory effects on ear swelling (Fig. 2B) . To negate the possibility that the inability of anti-CD80 mAb to inhibit ear swelling resulted from a suboptimal dose or lower efficacy of the RM80 mAb, we compared RM80 with another anti-CD80 mAb, 1G10, and obtained substantially identical results (not shown). Furthermore, the treatment with a combination of both RM80 and PO3 did not significantly affect the ear swelling more than the results observed with PO3 alone.
The efficacy of in vivo treatment with anti-CD86 mAb was also demonstrated by histological examination. Figure 3 shows representative samples of ears unsensitized (Fig. 3a) or treated with either PBS (Fig. 3b), RM80 (Fig. 3c) or PO3 (Fig. 3d) . Histological examination of the PBS-treated mice showed severe swelling, edema and abundant leukocyte infiltration, in comparison to unsensitized mice. However, the ears from the PO3-treated mice demonstrated an almost complete absence of swelling, edema and cellular infiltration. Consistent with the results of the ear swelling assay, histologically, no obvious improvement was observed in the RM80-treated mice (Rg. 3c). These results clearly demonstrate that the in vivo treatment with anti-CD86, but not anti-CD80 mAb, efficiently inhibits the hapten-induced CH reactions elicited by epicutaneous sensitization in an induction phase.
Migrate LC in the dermis express abundant CD86 24 h after sensitization
We investigated further the possibility that this dominant effect of anti-CD86 mAb resulted from the preferential expression of CD86 on APC in the CH reactive site. It was previously reported that phenotypic and functional change of LC in the epidermis occurred within 24 h after application of haptens (15) . We, therefore, examined the expression of MHC class II, CD80 and CD86 in the skin 24 h after primary application with hapten. Figure 4 shows the results of immunohistochemical staining with anti-MHC class II (M5/114) (Fig. 4a, d  and g ), anti-CD80 (RM80) (Fig. 4b, e and h ) and anti-CD86 (PO3) (Fig. 4c, f and i ) mAb in the ears from mice unsensitized control (Fig. 4a-c) , 24 h after the primary sensitization with 0.2% DNFB (Fig. 4d-f ) and the anti-CD86 mAb treated mice 24 h after DNFB challenge (Fig. 4g-i) . Consistent with the previous report, we observed that numerous cells morphologically resembling DC expressed MHC class II antigen in control sections (Fig. 4a) . These cells were detected in the basal layer of epidermis, as well as dermis. The numbers of MHC class ll-positive cells were clearly increased at 24 h after hapten application (Fig. 4d) . Although CD80 or CD86 positive cells were hardly detected in control sections (Fig.  4b and c) , the cells strongly expressing CD86 were observed 24 h after primary sensitization (Fig. 4f) . It should be noted that most of CD86 + cells were found in the subepidermal zone, but not within the epidermis. The CD86 + cells in upper dermis appeared to be LC from their morphology, and the CD86 + cells in the deeper layer of the dermis appeared to consist of both LC and macrophages. In contrast, we could hardly detect any CD80 positive cells even after hapten painting (Fig. 4e) . Although an obvious difference was not observed in the expression of MHC class II and CD86 in the sensitized and challenged-ears, as compared with the ears after primary hapten application, a few weakly CD80 positive cells were detected (not shown). Interestingly, anti-CD86 treatment, but not anti-CD80 treatment (not shown), clearly reduced the number of CD86 expressing cells and decreased the number of MHC class II positive cells to the control level ( Fig. 4g-i) .
Lymph node DC from the CH-elicited mice express both CD80 and CD86
It was reported that LC migrate to draining lymph nodes and that the increase in the number of DC with antigens in the regional lymph nodes was detected within 30 min, reached a peak at -24 h and returned to normal levels by day 6 after skin painting (27) . We, therefore, investigated the CD80 and CD86 expression in draining regional lymph nodes 24 h after challenge (Fig. 5) . The location of the B cell follicles and T cell areas were distinguished by the comparative staining with anti-CD4 and anti-MHC class II mAb (not shown). It was reported that, in normal lymph nodes, DC expressing CD86 but not CD80 were found mainly in the T cell area as previously described (6) . In the draining lymph node from the unsensitized mice, scattered CD86 + DC (Fig. 5b) were observed mostly in the T cell-rich areas, which was stained positive with anti-CD4 mAb. In contrast, no apparent CD80 + cells were observed (Fig. 5a) . No positive staining with the anti-CD80 or anti-CD86 mAb was detected on cells that morphologically resembled B cells in the cortical areas. The lymph node from the sensitized and challenged mice strongly expressed CD80 (c) and CD86 (d), preferentially in the T cellrich area, in parallel with the MHC class II expression (not shown). The cell profiles at higher magnification indicated that these positive cells were mostly DC and some macrophages but not T cells. The numbers of CD80 + and CD86 + cells were moderately reduced by the anti-CD86 treatment ( Fig. 5e and f) . These results suggest that the anti-CD86 mAb treatment abrogated the subsequent interaction of DC and T cells in the regional lymph nodes by inhibiting the primary interaction between naive T cells and the antigen-bearing LC. Furthermore, it is likely that the failure of the anti-CD80 mAb treatment to effect in the induction phase of CH responses resulted from the relative lack or low expression of CD80, or non-functional expression on LC at the time of sensitization. However, once the antigen is presented by LC expressing CD86, both CD80 and CD86 were comparably induced by the consecutive reactions in the lymph node.
• 
Hapten-specific T cell proliferation is inhibited by the anti-CD86 mAb treatment.
To determine whether draining lymph node T cells from mice treated with anti-CD86 mAb become hyporesponsive to the sensitized antigen, we examined the in vitro proliferative responses. Purified lymph node T cells from TNCB-sensitized or unsensitized mice were co-cultured with TNBS (water soluble analogue of TNCB)-pulsed or unpulsed intact syngeneic splenocytes for 72 h. Unsensitized T cells failed to proliferate in response to either TNBS-pulsed or unpulsed splenocytes. Lymph node T cells from TNCB-sensitized mice showed a -3-fold higher proliferative response when stimulated in vitro with TNBS-pulsed splenocytes (Fig. 6 ). The treatment with anti-CD86 mAb (P03) in vivo significantly reduced the proliferative response to TNBS, whereas the in vivo treatment with anti-CD80 mAb (RM80) failed to inhibit proliferative responses. Lymph node T cells from RM80-treated mice consistently exhibited a higher proliferative response to unpulsed syngeneic splenocytes than the other three groups (Fig. 6B) . Further studies are required to determine the reason for this observation. Taken together, our data indicate that contact allergen-specific T cell responses can be inhibited by the anti-CD86 mAb treatment in the induction phase of CH reactions. 
win-
Either treatment with anti-CD80 or CD86 mAb in the effector phase partially inhibits CH responses
We next determined whether anti-CD80 and/or anti-CD86 treatment would modulate the CH responses in the effector phase. DNFB-sensitized mice were treated with controlreagents, RM80, PO3 or both 2 h prior to challenge and the ear swelling was measured 24 h after challenge. The data represent a summary of four experiments from 22 to 26 mice per group (Fig. 7) . Although there were marked individual variations in the ear thickness after treatment, partial but statistically significant (P < 0.005) inhibitory effects were observed in either anti-CD80 or anti-CD86 mAb-treated group, as compared to the PBS-treated group. We have not observed any additive effects by a combination of both mAb. These results suggest a partial contribution of both CD80 and CD86 in the effector phase of CH reactions and the presence of some CD80/CD86-independent mechanism.
Discussion
The co-stimulatory pathway mediated by CD28 has been implicated in various immune responses and is an important target for immune intervention. CTLA-4-lg treatment, which blocks the interactions of CD28 on T cells with CD80 and CD86 counter-receptors on APC, has succeeded in inhibiting immune responses in the various experimental models in vivo (28) (29) (30) (31) (32) (33) (34) . However, the mechanisms for immunosuppression and induction of tolerance have not yet been completely defined. In this study, we demonstrated the differential roles of CD80 and CD86 co-stimulatory molecules in two distinct phases of CH reactions. Our results revealed that CD86, but not CD80, plays a potent role in the induction phase of CH reactions, which is mediated by the interaction of antigenbearing LC and naive T cells. Recently, several studies suggest the distinct co-stimulatory signal between CD80 and CD86 or the preferential contribution of CD86-mediated signals to T h 2 cell differentiation (35) (36) (37) (38) . However, it is a general agreement that the CH response results from cellular immune responses mainly mediated by Tf,1 cells from T cell transfer experiments and the T h 1 cytokine blocking studies. Therefore, the dominant effect of anti-CD86 mAb in this model is unlikely to relate with the balance between T h 1-and 1^2-mediated immune responses.
It is known that epidermal LC are specialized APC in epithelial tissues derived from bone marrow and play key roles in the induction of T cell-mediated immunity against environmental, infectious and tumor-associated antigens in the skin. However, resident LC in the epidermis and the LC freshly isolated from normal skin are inefficient with regard to their capacity to induce antigen-specific T cell proliferation, as compared with DC derived from lymph nodes, spleen and peripheral blood (39) (40) (41) . Within 24 h after antigen application, LC in the epidermis increase in size and in their expression of MHC class II and exhibit an enhanced capability for inducing T cell proliferation (15) . Our immunohistochemical examination of the contact allergen-sensitized skin demonstrated a selective up-regulation of CD86 on LC in the dermis. We could not detect substantial staining of CD80 on LC in the skin 24 h after the primary sensitization or after the secondary challenge. It was reported that CD80 expression on LC was induced by in vitro culture with cytokines such as granulocyte macrophage colony stimulating factor (GM-CSF), tumor necrosis factor-a, IL-1a, IL-ip and IL-4 (14) although the expression of CD86 was much higher than CD80 (13) . Similar findings were obtained from studying cultured human peripheral blood DC and monocytes (7, 42, 43) .
At present, there is no information on the differential regulation of CD80 and CD86 in LC after the in vivo antigen stimulation. Our study demonstrates the dominant up-regulation of CD86 expression after specific-antigen stimulation in situ. Similar to our findings on LC, B cells activated with a combination of anti-n and IFN-yor anti-lgD-dextran preferentially increased CD86 expression in correlation with antigen presentation activity (44, 45) . Abundant expression of CD86 on LC after sensitization seems to correlate with the functional ability of skin-associated APC to induce initial T cell responses to allergen. Our data further indicate that the treatment with anti-CD86 mAb induces a contact allergen-specific T cell unresponsiveness in the induction phase of CH. As the absence of co-stimulation in antigen presentation may lead to T cell anergy, blocking of the interaction of LC with T cells using the anti-CD86 mAb may induce tolerance in the reaction of naive T cells to APC. Our results that lymph node T cells did not respond to secondary stimulation in vitro and in vivo suggests the T cell responses were inhibited by the treatment with anti-CD86 mAb. Rechallenging after a prolonged period will clarify whether antigen-specific tolerance is induced. We cannot completely exclude the possibility that the administration of anti-CD86 mAb itself may modify the migration of LC to lymph nodes. However, we have confirmed that PO3 mAb was not associated with the depletion of target cells in our previous studies (24) and the signaling capacity by anti-CD86 mAb was not confirmed at present. Therefore it seems unlikely that the binding of PO3 mAb to LC affected the migration. Further studies using monovalent mAb fragments might answer this question. In addition, the failure of suppression with the anti-CD80 mAb in secondary responses may result from the low expression of CD80 on LC in the initial sensitization with allergen. Alternatively, CD80 might deliver a regulatory signal interacting with one of its counter receptors, CTLA-4 (46). Recently, negative regulatory roles of CTLA-4 were demonstrated by the studies using CTLA-4 deficient mice (47, 48) . If it is the case that CD80 is a major functional •receptor for CTLA-4, the spontaneous higher proliferative responses of T cells derived from the anti-CD80 treated mice might be explained.
Administration of either anti-CD80 or CD86 mAb in the effector phase comparably reduced CH reactions. This result can be explained from the equivalent expression of both CD80 and CD86 in draining lymph node DC in the sensitized mice. After the ear challenge, DC expressing both CD80 and CD86 may present antigens transported by LC and rapidly activate memory T cells which quickly migrate into the challenged site. Furthermore the fact that mice initial treated with anti-CD86 mAb reduced CD80 and CD86 expression on lymph node DC suggests that the interaction of CD86-bearing LC with T cells is essential for up-regulation of CD80 and CD86 in lymph node DC. Previous reports demonstrated that LC migrate from epidermis to the dermis and transport antigens to regional draining lymph node via lymphatic vessels within 24 h after skin painting and initiate T cell activation (16, 27, 40, 49) . Based on this concept, the expression of CD80 and CD86 on DC may be induced by cytokines secreted in the initial activation of naive T cells. Since GM-CSF and IFN-y produced by T cells are capable of inducing CD80 and CD86 on DC (12) , these factors may work as potent regulators of lymph node DC.
Despite the treatment with both anti-CD80 and CD86 mAb, we failed to obtain complete inhibition of CH responses at an effector phase. The early phase of CH reactions (within the first 24 h after challenge) manifests characteristic neutrophil infiltration and edema, which is mediated by leukocyte adhesion to vascular endothelium. Predominant lymphocyte infiltration was observed at 48 and 72 h. Therefore other receptor/ ligand pairs that permit adhesion of cells to endothelium, such as the very late antigen molecule-4/vascular cell adhesion molecules-1 and intercellular adhesion molecule-1 (CD54)/ leukocyte function-associated molecule-1 (CD11a/CD18) may be involved in the early phase of these reactions (50, 51) .
Taken together, we demonstrated that CD86 plays a dominant role in the interaction between migratory LC and naive T cells in the draining lymph nodes after epicutaneous application of hapten. Blockade of the CD86-CD28 co-stimulatory pathway in the induction phase could inhibit contact allergenspecific T cell responses. However, CD80 and CD86 are not essential for the effector functions involved in CH reactions. Our present findings will be useful for elucidating the pathogenesis of allergic CH in humans.
